US 12,215,338 B2
Adeno-associated virus (AAV) delivery of anti-FAM19A5 antibodies
Jong-Mook Kim, Seoul (KR); Dong Sik Kim, Seoul (KR); Juwon Shim, Seoul (KR); and Soon-gu Kwon, Seoul (KR)
Assigned to Neuracle Science Co., Ltd., Seoul (KR); and Neuracle Genetics, Seoul (KR)
Appl. No. 17/053,733
Filed by Neuracle Science Co., Ltd., Seoul (KR); and Neuracle Genetics, Seoul (KR)
PCT Filed May 8, 2019, PCT No. PCT/IB2019/053791
§ 371(c)(1), (2) Date Nov. 6, 2020,
PCT Pub. No. WO2019/215644, PCT Pub. Date Nov. 14, 2019.
Claims priority of provisional application 62/668,634, filed on May 8, 2018.
Prior Publication US 2021/0388382 A1, Dec. 16, 2021
Int. Cl. A61K 48/00 (2006.01); C07K 16/24 (2006.01); C12N 15/86 (2006.01); A61K 39/00 (2006.01)
CPC C12N 15/86 (2013.01) [C07K 16/24 (2013.01); A61K 2039/505 (2013.01); C07K 2317/622 (2013.01); C07K 2317/76 (2013.01); C12N 2750/14141 (2013.01); C12N 2800/22 (2013.01)] 20 Claims
OG exemplary drawing
 
1. An adeno-associated virus (AAV) vector comprising a nucleic acid that encodes an antibody, or an antigen-binding portion thereof, which specifically binds to a family with sequence similarity 19, member A5 (FAM19A5) protein (anti-FAM19A5 antibody), wherein the anti-FAM19A5 antibody comprises a heavy chain CDR1, CDR2, and CDR3 and a light chain CDR1, CDR2, and CDR3, and wherein:
(i) the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 16;
(ii) the heavy chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 212;
(iii) the heavy chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 213;
(iv) the light chain CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 222;
(v) the light chain CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 225; and
(vi) the light chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 224.